Cabio Biotech expects a net loss of about 101 million yuan in the first half, swinging from profit to loss year-on-year

央广财经··Read original
3▲0 ▼1Impact / 5
Summary · why it matters

Cabio Biotech has released its 2026 half-year performance forecast, expecting a net loss attributable to owners of the parent company of about 101 million yuan in the first half, compared with a profit of 108 million yuan in the same period last year. The company said that due to the impact of overseas market sentiment and new regulatory requirements, production plans have been adjusted, and measures have been taken to promote business recovery. As product production and sales have not yet fully recovered, overall performance still shows a significant gap compared with the same period last year.

Impact on assets 1

Others▼
Cabio Biotech Wuhan Co Ltd
688089
▼ NegativeRegulationrelevance

Company expects net loss due to overseas market sentiment and new regulatory requirements impacting production and sales.